Skip to content
Revelation News
Sign inSign up
Vera's Trutakna Demonstrates Strong Final Results in Phase 3 Kidney Disease Trial
Health

Vera's Trutakna Demonstrates Strong Final Results in Phase 3 Kidney Disease Trial

Source Summary

Vera Therapeutics' Trutakna achieved positive final results in a Phase 3 trial for IgAN (immunoglobulin A nephropathy), stabilizing kidney function in patients. The drug reduced the risk of death and other serious complications in IgAN patients. These results support potential regulatory approval for the treatment.

Why it matters

Positive Phase 3 results for a kidney disease treatment advance the potential for a new therapeutic option for IgAN patients with limited current treatment alternatives.

Read the Source

NASDAQ:VERALive chart